[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623976":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":21,"centralContacts":31,"locations":37,"responsibleParty":70,"collaborators":21,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":21,"enrollmentInfo":84,"targetDuration":21,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":21,"overallStatus":40,"whyStopped":21,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"Azienda Ospedaliero-Universitaria di Parma","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Haematological neoplasms or neoplasms of solid organs","* Patients with a confirmed diagnosis of hematological malignancy or solid organ malignancy, including solid or hematological malignancies characteristic of pediatric age.\n* Patients diagnosed with hematological or solid neoplasms defined as high risk, according to biological and clinical characteristics, including metastatic cases, or diagnosed with recurrent and\u002For refractory hematological or solid neoplasms.",[12,13,14],"Biological: Functional tests","Other: Multi-omics analyses","Genetic: Cytogenetics\u002F FISH",[16,22,26],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"BIOLOGICAL","Functional tests","Functional analyses will be performed on primary sample from each enrolled patient. Malignant cells are cultered and incubated with a specific library of drugs (300 drugs) at four different concentrations for 72 hours.",[9],null,{"type":6,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Multi-omics analyses","Our scientific approach is based on various investigations, including radiomics, digital pathology, immune profiling, bulk transcriptomics, single-cell resolution, single-cell transcriptomics, phosphoproteomics, functional immunoprofiling, and inflammasome analysis, NGS (Next Generation Sequencing analysis).",[9],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":21},"GENETIC","Cytogenetics\u002F FISH","Individual biopsy samples will be evaluated in a pipeline that includes established diagnostic elements, e.g., cytogenetics and FISH.",[9],[32],{"name":33,"role":34,"phone":35,"phoneExt":21,"email":36},"Giovanni Roti, Associate Professor","CONTACT","+39 0521 702200","giovanni.roti@unipr.it",[38,56],{"facility":39,"status":40,"city":41,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"AO Riuniti Villa Sofia-Cervello di Palermo","RECRUITING","Palermo","90146","Italy","IT",{"type":46,"coordinates":47},"Point",[48,49],13.3636,38.1166,{"lat":49,"lon":48},[52],{"name":53,"role":34,"phone":54,"phoneExt":21,"email":55},"Alessandra Santoro","+ 39 091-7803143","alessandra.santoro01@unipa.it",{"facility":57,"status":40,"city":58,"state":58,"zip":59,"country":43,"countryCode":44,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"University of Perugia","Perugia","06123",{"type":46,"coordinates":61},[62,63],12.38878,43.1122,{"lat":63,"lon":62},[66],{"name":67,"role":34,"phone":68,"phoneExt":21,"email":69},"Roberta La Starza, Medical doctor, PhD","+39 075 5783455","roberta.lastarza@unipg.it",{"type":71,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":74,"oldNameTitle":21,"oldOrganization":21},"PRINCIPAL_INVESTIGATOR","Giovanni Roti","Full Professor","University of Parma","100623976","integrative-multi-omics-and-functional-platform-for-the-complete-diagnostic-characterization-of-tumors-the-italian-tumor-chemogenomic-profiler-it-tcp-100623976",false,"NCT07403630","INTEGRATIVE \"MULTI-OMICS\" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)","IT-TCP POS","Inclusion criteria:\n\n* Patients aged one year and over who are referred to the centres involved in the protocol (Azienda Ospedaliero-Universitaria di Parma, University of Parma, University of Perugia and Azienda Ospedali Riuniti Villa Sofia-Cervello of Palermo).\n* Patients with an established diagnosis of haematological or solid organ malignancy, including haematological or solid malignancies characteristic of the paediatric age group.\n* Patients diagnosed with relapsed, refractory and\u002For metastatic haematological or solid malignancy. Patients may be enrolled regardless of the extent and type of previous therapy. Patients may also be enrolled if they are undergoing active treatment at the time of evaluation.\n* Patients must have the capacity to understand the investigative nature of the study and provide informed consent in writing. For patients under the age of 12 years, consent will be provided by the parent\u002Flegal guardian according to international guidelines. For patients aged 12 to 17 years, consent will be provided by the patient and the parent\u002Flegal guardian according to the mature minor principle.\n\nExclusion criteria:\n\n* Patients younger than 1 year old\n* Patients with active, uncontrolled infections","ALL","1 Year",{"count":85,"type":86},300,"ESTIMATED","INTERVENTIONAL",[89],"NA","This is a multicenter, experimental preclinical study conducted on primary samples from patients diagnosed with hematological or solid neoplasms defined as high risk. The study will be prospective, based on the consecutive enrollment of eligible patients at each participating institution.",[92,93,94,95,96,97,98,99,100,101,102,103],"Acute Leukemia","Multiple Myeloma","Squamous Cell Carcinoma","Pleural Mesothelioma","Pancreatic Cancer","Bladder Cancer","Ovarian Cancer","Melanoma","Pediatric Acute Lymphoblastic Leukemia","Chronic Leukemia","Myeloproliferative Disorders","Myelodysplastic Disorders","2026-02-13",{"date":106,"type":107},"2026-02-17","ACTUAL",{"date":109,"type":107},"2023-05-31",{"date":111,"type":86},"2028-02-12",{"name":5,"class":6},2]